Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma

Fig. 4

Maintenance of NK cell subsets in patients after NMP treatment. Flow cytometry analysis of PBMC from 10 patients collected pre-treatment (PRE) and after cycles 2–3 (POST) of NMP therapy. A NK cells (CD56+CD3−CD19−) are shown as a percentage of live lymphocytes, and B immature (CD16−CD56hi), C regulatory (CD16-CD56+) and D mature (CD16+CD56+) NK cell subsets are shown as a percentage of live NK cells. Expression of TIGIT (E–G), CD96 (H–J) and DNAM1 (K–M) was calculated using the geometric mean of the mature, regulatory and immature NK cell subsets. *p = 0.0371

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us